After MEDCAC vote, CMS CAR T coverage could come down to PROs

CMS's Medicare Evidence Development & Advisory Committee voted that there is sufficient evidence to support the use of four different patient-reported outcome tools that could be used in future studies of CAR T cell therapies. The decision sets up the possibility that gathering information via one of these PROs could be a prerequisite for coverage under a pending National Coverage Determination for Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel.

CMS held the Wednesday meeting to

Read the full 736 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE